PRX-102 Given to 1st Patient in US Under Expanded Access Program
News
A first patient has been treated with PRX-102 (pegunigalsidase alfa), an investigational enzyme replacement therapy for Fabry disease that is under review for approval, through an expanded access program (EAP) in the United States. ... Read more